
CLAIMS

1. A crystalline form of compound (I), 4-{(1S, 2S)-2-[(4-cyclobutylpiperazin-1-yl)carbonyl]-cyclopropyl}-benzamide,



(I).

2. A crystalline form of compound (I) of claim 1, characterized in that said form has an XRPD pattern (Cu Kα) with at least one peak at about 18.3 °2Theta, when measured using radiation with a wavelength of about 1.54 angstroms.

3. A crystalline form of compound (I) of claim 1, characterized in that said form has an XRPD pattern (Cu Kα) with at least two peaks at about 4.9 and about 18.3 °2Theta, when measured using radiation with a wavelength of about 1.54 angstroms.

4. A crystalline form of compound (I) of claim 1, characterized in that said form has an XRPD pattern (Cu Kα) with at least three peaks at about 4.9, about 18.3 and about 20.4 °2Theta when measured using radiation with a wavelength of about 1.54 angstroms.

5. A crystalline form of compound (I) of claim 1, characterized in that said form has an XRPD pattern (Cu Kα) with at least four peaks at about 4.9, about 18.3 about 19.6 and 20.4 °2Theta, when measured using radiation with a wavelength of about 1.54 angstroms.

6. A crystalline form of compound (I) of any one of claims 3-5, wherein the XRPD pattern (Cu Kα) further comprises peaks at about 16, 4 and about 16.6, about 18.3 and about 19.6 °2Theta, when measured using radiation with a wavelength of about 1.54 angstroms.

7. A crystalline form of compound (I) of any one of claims 3-6, wherein the XRPD pattern (Cu Kα) further comprises a peak at about 5.3 °2Theta, when measured using radiation with a wavelength of about 1.54 angstroms.

8. A crystalline form of compound (I) of claim 1, characterized in that said form has an XRPD pattern (Cu Kα) with peaks at about 4.9, about 5.3, about 9.0, about 12.6, about 16.4, about 16.6, about 18.3, about 19.6, about 20.4, about 21.2, about 23.2 and about 24.6 °2Theta when measured using radiation with a wavelength of about 1.54 angstroms.

9. A crystalline form of compound (I) of claim 1, characterized by the XRPD pattern essentially as shown in Figure 1.

10. A crystalline form of compound (I) of any one of claims 3-9, characterized by the DSC thermogram comprising an endotherm at about 235°C.

11. A crystalline form of compound (I) of claim 10, characterized by the DSC thermogram comprising an additional small endotherm at about 225°C.

12. A crystalline form of compound (I) of any one of claims 3-9, characterized by the DSC thermogram essentially as shown in Figure 2.

13. A crystalline form of compound (I) of any one of claims 1-12, which is substantially pure.

14. A pharmaceutical formulation comprising a crystalline form of compound (I) as claimed in any one of claims 1-13 in association with a pharmaceutically acceptable adjuvant, diluent and/or carrier.

15. A crystalline form of compound (I) according to any one of claims 1-13 for use in therary.

16. Use of a crystalline form of compound (I) according to any one of claims 1-13 in the manufacture of a medicament for the treatment of a disorder selected from schizophrenia, narcolepsy, excessive daytime sleepiness, obesity, attention deficit hyperactivity disorder, pain, neuropathic pain, Alzheimer's disease, cognition deficiency, and cognition deficiency associated with schizophrenia.

17. A crystalline form of compound (I) according to any one of claims 1-13 for use in the treatment of schizophrenia, narcolepsy, excessive daytime sleepiness, obesity, attention deficit hyperactivity disorder, pain, neuropathic pain, Alzheimer's disease, cognition deficiency, and cognition deficiency associated with schizophrenia.

CLAIMS

1. An invention not claimed in any divisional application.